Rosiglitazone inhibits proliferation of renal proximal tubular cells via down-regulation of ERK and Akt

Renal Failure

Volumn 32, Issue 1, 2010, Pages 103-111

  Choi, Im Jeong ^a   Kim, Su Yung ^a   Kwon, Chae Hwa ^a   Kim, Yong Keun ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Cell arrest; Cell proliferation; ERKAkt; PPAR ; Renal epithelial cells

Indexed keywords

CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE B; ROSIGLITAZONE;

ANIMAL CELL; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; KIDNEY PROXIMAL TUBULE; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; WESTERN BLOTTING;

EID: 76449092879     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860220903391259     Document Type: Article

References (59)

1. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803-812.
2. Kliewer SA, Willson TM. The nuclear receptor PPARgamma- bigger than fat. Curr Opin Genet Dev. 1998;8:576-581.
3. Rosen ED, Spiegelman BM. PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001;276:37731-37734.
4. Kim EJ, Park KS, Chung SY, Sheen YY, Moon DC, Song YS, Kim KS, Song S, Yun YP, Lee MK, Oh KW, Yoon do Y, Hong JT. Peroxisome proliferator-activated receptor-gamma activator 15-deoxy-Delta12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: Association with extracellular signal-regulated kinase signal pathway. J Pharmacol Exp Ther. 2003;307:505-517.
5. Sugimura A, Kiriyama Y, Nochi H, Tsuchiya H, Tamoto K, Sakurada Y, Ui M, Tokumitsu Y. Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun. 1999;261:833-837.
6. Toyoda Y, Tsuchida A, Iwami E, Miwa I. Toxic effect of troglitazone on cultured rat hepatocytes. Life Sci. 2001; 68:1867-1876.
7. Jung JY, Yoo CI, Kim HT, Kwon CH, Park JY, Kim YK. Role of mitogen-activated protein kinase (MAPK) in troglitazone- induced osteoblastic cell death. Toxicology. 2007; 234:73-82.
8. Kang DW, Choi CH, Park JY, Kang SK, Kim YK: Ciglitazone induces caspase-independent apoptosis through downregulation of XIAP and surviving in human glioma cells. Neurochem Res. 2008;33:551-561.
9. Lee SJ, Kim MS, Park JY, Woo JS, Kim YK. 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis via JNK-mediated mitochondrial pathway in osteoblastic cells. Toxicology. 2008; 248:121-129.
10. Parameswaran N, Hall CS, Bomberger JM, Sparks HV, Jump DB, Spielman WS. Negative growth effects of ciglitazone on kidney interstitial fibroblasts: Role of PPAR-gamma. Kidney Blood Press Res. 2003;26:2-9.
11. Zafiriou S, Stanners SR, Saad S, Polhill TS, Poronnik P, Pollock CA. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol. 2005;16:638-645.
12. Arici M, Chana R, Lewington A, Brown J, Brunskill NJ. Stimulation of proximal tubular cell apoptosis by albuminbound fatty acids mediated by peroxisome proliferator activated receptor-gamma. J Am Soc Nephrol. 2003;14:17-27.
13. Kang DS, Kwon CH, Park JY, Kim JH, Woo JS, Jung JS, Kim YK. 15-deoxy-Delta12,14-prostaglandin J2 induces renal epithelial cell death through NF-kappaB-dependent and MAPK-independent mechanism. Toxicol Appl Pharmacol. 2006;216:426-435.
14. Kwon CH, Yoon CS, Kim YK. Ciglitazone induces caspase-independent apoptosis via p38-dependent AIF nuclear translocation in renal epithelial cells. Toxicology. 2007;244:13-24.
15. Giral H, Villa-Bellosta R, Catalan J, Sorribas V: Cytotoxicity of peroxisome proliferator-activated receptor alpha and gamma agonists in renal proximal tubular cell lines. Toxicol In Vitro. 2007;21:1066-1076.
16. Chana RS, Lewington AJ, Brunskill NJ. Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: Thiazolidinediones are partial PPAR gamma agonists. Kidney Int. 2004; 65:2081-2090.
17. Tsuchiya T, Shimizu H, Shimomura K, Mori M. Troglitazone inhibits isolated cell proliferation, and induces apoptosis in isolated rat mesangial cells. Am J Nephrol. 2003;23: 222-228.
18. Doi S, Masaki T, Arakawa T, Takahashi S, Kawai T, Nakashima A, Naito T, Kohno N, Yorioka N. Protective effects of peroxisome proliferator-activated receptor gamma ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury. Transplantation. 2007; 84:207-213.
19. Sivarajah A, Chatterjee PK, Patel NS, Todorovic Z, Hattori Y, Brown PA, Stewart KN, Mota-Filipe H, Cuzzocrea S, Thiemermann C: Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol. 2003;23:267-276.
20. Matsuyama M, Yoshimura R, Hase T, Uchida J, Tsuchida K, Takemoto Y, Kawahito Y, Sano H, Nakatani T. Expression of peroxisome proliferator-activated receptor-gamma in renal ischemia-reperfusion injury. Transplant Proc. 2005;37: 1684-1685.
21. Yousefipour Z, Hercule H, Truong L, Oyekan A, Newaz M. Ciglitazone, a peroxisome proliferator-activated receptor gamma inducer, ameliorates renal preglomerular production and activity of angiotensin II and thromboxane A2 in glycerol- induced acute renal failure. J Pharmacol Exp Ther. 2007;322:461-468.
22. Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, Usui H, Wada J, Shikata Y, Makino H. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol. 2007;292: F1141-1150.
23. Okada T, Wada J, Hida K, Eguchi J, Hashimoto I, Baba M, Yasuhara A, Shikata K, Makino H. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes. 2006;55:1666-1677.
24. Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, Latter AJ, Lawrie KW, Mossakowska D, Murphy GJ, Roxbee Cox L, Smith SA. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 1998;284:751-759.
25. Buckingham RE, Al-Barazanji KA, Toseland CD, Slaughter M, Connor SC, West A, Bond B, Turner NC, Clapham JC. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes. 1998;47: 1326-1334.
26. Baylis C, Atzpodien EA, Freshour G, Engels K. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther. 2003;307:854-860.
27. Lee S, Kim W, Moon SO, Sung MJ, Kim DH, Kang KP, Jang YB, Lee JE, Jang KY, Park SK. Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant. 2006;21:2096-2105.
28. Yu X, Li C, Li X, Cai L. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1. Toxicol Sci. 2007;96:346-356.
29. Sommer M, Wolf G. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide. Am J Nephrol. 2007;27:425-434.
30. Nowak G, Price PM, Schnellmann RG. Lack of a functional p21WAF1/CIP1 gene accelerates caspase-independent apoptosis induced by cisplatin in renal cells. Am J Physiol Renal Physiol. 2003;285:F440-F450.
31. Zhou H, Kato A, Yasuda H, Miyaji T, Fujigaki Y, Yamamoto T, Yonemura K, Hishida A. The induction of cell cycle regulatory and DNA repair proteins in cisplatininduced acute renal failure. Toxicol Appl Pharmacol. 2004;200:111-120.
32. Miyaji T, Kato A, Yasuda H, Fujigaki Y, Hishida A. Role of the increase in p21 in cisplatin-induced acute renal failure in rats. J Am Soc Nephrol. 2001;12:900-908.
33. Megyesi J, Safirstein RL, Price PM. Induction of p21WAF1/ CIP1/SDI1 in kidney tubule cells affects the course of cisplatin- induced acute renal failure. J Clin Invest. 1998;101: 777-782.
34. Megyesi J, Andrade L, Vieira JM Jr, Safirstein RL, Price PM. Positive effect of the induction of p21WAF1/CIP1 on the course of ischemic acute renal failure. Kidney Int. 2001;60:2164-2172.
35. Weissgarten J, Berman S, Efrati S, Rapoport M, Averbukh Z, Feldman L. Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats. Nephrol Dial Transplant. 2006;21:1198-1204.
36. Efrati S, Berman S, Ilgiyeav E, Averbukh Z, Weissgarten J. PPAR-gamma activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats. Nephron Exp Nephrol. 2007;106: e107-e112.
37. Eucker J, Bangeroth K, Zavrski I, Krebbel H, Zang C, Heider U, Jakob C, Elstner E, Possinger K, Sezer O. Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma. Anticancer Drugs. 2004;15: 955-960.
38. Morosetti R, Servidei T, Mirabella M, Rutella S, Mangiola A, Maira G, Mastrangelo R, Koeffler HP. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int J Oncol. 2004;25: 493-502.
39. Al-Rasheed NM, Chana RS, Baines RJ, Willars GB, Brunskill NJ. Ligand-independent activation of peroxisome proliferator-activated receptor-gamma by insulin and C-peptide in kidney proximal tubular cells: Dependent on phosphatidylinositol 3-kinase activity. J Biol Chem. 2004;279:49747-49754.
40. Harbour JW, Dean DC. The Rb/E2F pathway: Expanding roles and emerging paradigms. Genes Dev. 2000;14:2393-2409.
41. Choudhury GG, Karamitsos C, Hernandez J, Gentilini A, Bardgette J, Abboud HE. PI-3-kinase and MAPK regulate mesangial cell proliferation and migration in response to PDGF. Am J Physiol. 1997;273:F931-F938.
42. Gille H, Downward J. Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem. 1999; 274:22033-22040.
43. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/ AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006;46:249-279.
44. Kanjanabuch T, Ma LJ, Chen J, Pozzi A, Guan Y, Mundel P, Fogo AB. PPAR-gamma agonist protects podocytes from injury. Kidney Int. 2007;71:1232-1239.
45. Gouni-Berthold I, Berthold HK, Weber AA, Ko Y, Seul C, Vetter H, Sachinidis A. Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway. Naunyn Schmiedebergs Arch Pharmacol. 2001;363: 215-221. (Pubitemid 32200330)
46. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1'S transition in vascular smooth muscle cells. J Biol Chem. 2000;275: 22435-22441.
47. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998;273:25573-25580.
48. Kitamura S, Miyazaki Y, Hiraoka S, Nagasawa Y, Toyota M, Takakura R, Kiyohara T, Shinomura Y, Matsuzawa Y. PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in rastransformed rat intestinal epithelial cells. Int J Cancer. 2001; 94:335-342.
49. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab. 2001; 86:2170-2177.
50. Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, Ma XL. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res. 2004; 62:135-144.
51. Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martinez A, Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem. 2005;280:21453-21462.
52. Ward JE, Gould H, Harris T, Bonacci JV, Stewart AG. PPAR gamma ligands, 15-deoxy-delta12,14-prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms. Br J Pharmacol. 2004;141:517-525.
53. Fajas L, Egler V, Reiter R, Miard S, Lefebvre AM, Auwerx J. PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner. Oncogene. 2003;22:4186-4193.
54. Sheu WH, Ou HC, Chou FP, Lin TM, Yang CH. Rosiglitazone inhibits endothelial proliferation and angiogenesis. Life Sci. 2006;78:1520-1528.
55. Wymann MP, Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta. 1998;1436:127-150.
56. Chung JH, Ostrowski MC, Romigh T, Minaguchi T, Waite KA, Eng C. The ERK1/2 pathway modulates nuclear PTENmediated cell cycle arrest by cyclin D1 transcriptional regulation. Hum Mol Genet. 2006;15:2553-2559.
57. Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu MM. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol. 2003;23: 6139-6149.
58. Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi X, Jiang BH. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/ p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol. 2004;287:C281-C291.
59. Shelton JG, Blalock WL, White ER, Steelman LS, McCubrey JA. Ability of the activated PI3K/Akt oncoprotein to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. Cell Cycle. 2004;3:503-512.